Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Minimed

This article was originally published in The Gray Sheet

Executive Summary

Launches Model 407C infusion pump for general medication use following 510(k) clearance June 23. Similar to the firm's insulin infusion pumps and designed to deliver medications suitable for subcutaneous administration, the 407C represents diversification of the firm's technology to include disease states other than diabetes. MiniMed expects the device to be first used in connection with its alliance with United Therapeutics for the treatment of pulmonary hypertension

You may also be interested in...



MiniMed Continuous Glucose Monitor Rollout Expanding To 30 Centers In Q4

Expanded roll-out of MiniMed's continuous glucose monitor system to twenty-one additional U.S. centers will be completed by the end of November, the firm says.

MiniMed Continuous Glucose Monitor Rollout Expanding To 30 Centers In Q4

Expanded roll-out of MiniMed's continuous glucose monitor system to twenty-one additional U.S. centers will be completed by the end of November, the firm says.

Urologix Targis BPH Procedure Kit Sales Growth Spurs 38% August Stock Gain

Increased procedure kit sales for use with Urologix' Targis microwave catheter-based system for treatment of benign prostatic hyperplasia helped give the Minneapolis firm's stock a 38% boost in August.

Related Content

UsernamePublicRestriction

Register

MT012181

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel